Citations

Clear

3138 citation(s) found for "Smith, AM".

Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC).
Singh, Aditi P. , Parikh, Kaushal , Molina, Julian R. , Moffett, Jenesse Nicole , Schwecke, Anna J., Luce, A., Leventakos, Konstantinos , Owen, Dawn , Shanshal, Mohamed , Sridhar, Arthi , Mansfield, Aaron S. , Dimou, Anastasios , Smith, Katherine E. , Hazim, Antonious , Schwecke, Anna

Mayo Clinic

Journal of Clinical Oncology | June 26, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8071-8071

10.1200/jco.2024.42.16_suppl.8071 Get It

8071 Background: Data from the PACIFIC study demonstrated a 5-yr median progression free survival (PFS) and overall survival (OS) of 16.9 and 47.5 months respectively for patients with stage 3A and stage 3B NSCLC demonstrating a high risk of relapse. The 8th ed. of the IASLC staging project reports that the 60-month OS for stage 3A, B and C disease is 41%, 24% and 12% respectively, indicating that improved treatment options are needed for this patient population. Induction chemo-IO (ID chemo-IO) followed by concurrent chemo-radiation (CRT) has not been fully investigated due to concerns regarding the toxicity profile, but this may representant an important unexplored avenue for research. We aim to describe the outcomes of patients who received ID chemo-IO followed by CRT with or without maintenance IO. Methods: We conducted a retrospective study across all Mayo Clinic sites. Patients were included if they were diagnosed with Stage 3 NSCLC deemed ineligible for resection and/or requiring raditation over a large-field ] by a multidisciplinary team with plans for ID chemo-IO prior to CRT and maintenance IO. A total of 927 cases of stage 3 NSCLC patients were screened and those receiving ID chemo-IO followed by CRT were extracted (n = 36). Clinical endpoints are PFS, OS, overall response rate (ORR) and treatment related adverse events (TrAE) defined using CTCAE 5.0. Results: The median age was 67 years, 52.8% were female, all patients were past smokers and 97.2% identified as white. The tumor histologies were adenocarcinoma (66.67%), squamous (27.8%), mucinous adenocarcinoma (2.8%) and sarcomatoid (2.8%). Majority were Stage 3B (47.2%) followed by 3C (38.9%) and 3A (13.9%). N2 and N3 disease was noted in 36.1% and 55.6% of patients respectively. PD-L1 by IHC was > 1-49% (47.2%), > 50% (22.2%) and < 1% (19.4%). Patients received ID chemo-IO with pembrolizumab (83.3%), nivolumab (11.1%) and atezolizumab (2.78%). Average number of ID chemo-IO cycles were 3.67 cycles. The ORR to ID chemo-IO was 86.11%. The median PFS was 23.67 mths and the median OS was 32.07 months. About 94% of patients received CRT afterwards and 66.67% received maintenance IO with pembrolizumab (53.17%) or durvalumab (45.83%). Any grade TrAE occured in 58.33% of patients. Pneumonitis was the most common event (38.9%). Grade 3 -4 pneumonitis was noted in 28.5% (4/11) patients. Other toxicities included hepatitis (8.3%), colitis (11.1%) and myasthenia gravis (2.8%) and 22% of these TrAE’s were grade 3 or 4. Conclusions: Our results indicate that ID chemo-IO shows promise as a therapeutic approach for patients with unresectable stage III NSCLC, especially for patients deemed ineligible or high risk for upfront radiation. Further investigation is needed through a randomized clinical trial to systematically explore and validate the safety and efficacy of ID chemo-IO.
Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Pluvinage, John V. , Ngo, Thomas , Fouassier, Camille , McDonagh, Maura A. , Holmes, Brandon B. , Bartley, Christopher M. , Kondapavulur, Sravani , Hurabielle, Charlotte , Bodansky, Aaron , Pai, Vincent , Aslanpour, Ava , Alvarenga, Bonny D. , Zamecnik, Colin R. , Asencor, Andoni I., Huynh, Thanh Dat , Browne, Weston, Tubati, Asritha , Haney, Michael S. , Douglas, Vanja C. , Louiné, Martineau , Hauser, Stephen L. , Baranzini, Sergio E. , Wells, James A. , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth , Gillum, Leslie A. , Hales, Chadwick M. , Anderson, Mark S. , Smith, Bryan , Nath, Avindra , Green, Ari , Wilson, Michael R. , McDonagh, Maura , Hinman, Sam , Alvarenga, Bonny D , Zorn, Kelsey C , Zamecnik, Colin , Asencor, Andoni I , Huynh, Trung , Tubati, Asritha , Haney, Michael S , Louine, Martineau , Cree, Bruce Ac , Hauser, Stephen L. , Seeley, William , Baranzini, Sergio E , Wells, James A , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth S , Gillum, Leslie , Zikherman, Julie , Anderson, Mark S , Yazdany, Jinoos , Smith, Bryan , Nath, Avindra , Suh, Gina A , Flanagan, E P , Green, Ari J , Green, Ralph , Gelfand, Jeffrey M , DeRisi, Joseph L , Pleasure, Samuel J , Wilson, Michael R , Pluvinage, John V , Bodansky, Aaron , Hinman, Samuel S. , McCann, Adrian , Cree, Bruce , Seeley, William W. , Yazdany, Jinoos , Suh, Gina A. , Flanagan, Eoin P. , Gelfand, Jeffrey M.

Mayo Clinic

Science Translational Medicine | June 26, 2024 | Volume: 16 | Issue: 753 | Pages: No page available

10.1126/scitranslmed.adl3758 | PMID 38924428 Get It

Vitamin B12 is critical for hematopoiesis and myelination. Deficiency can cause neurologic deficits including loss of coordination and cognitive decline. However, diagnosis relies on measurement of vitamin B12 in the blood, which may not accurately reflect the concentration in the brain. Using programmable phage display, we identified an autoantibody targeting the transcobalamin receptor (CD320) in a patient with progressive tremor, ataxia, and scanning speech. Anti-CD320 impaired cellular uptake of cobalamin (B12) in vitro by depleting its target from the cell surface. Despite a normal serum concentration, B12 was nearly undetectable in her cerebrospinal fluid (CSF). Immunosuppressive treatment and high-dose systemic B12 supplementation were associated with increased B12 in the CSF and clinical improvement. Optofluidic screening enabled isolation of a patient-derived monoclonal antibody that impaired B12 transport across an in vitro model of the blood-brain barrier (BBB). Autoantibodies targeting the same epitope of CD320 were identified in seven other patients with neurologic deficits of unknown etiology, 6% of healthy controls, and 21.4% of a cohort of patients with neuropsychiatric lupus. In 132 paired serum and CSF samples, detection of anti-CD320 in the blood predicted B12 deficiency in the brain. However, these individuals did not display any hematologic signs of B12 deficiency despite systemic CD320 impairment. Using a genome-wide CRISPR screen, we found that the low-density lipoprotein receptor serves as an alternative B12 uptake pathway in hematopoietic cells. These findings dissect the tissue specificity of B12 transport and elucidate an autoimmune neurologic condition that may be amenable to immunomodulatory treatment and nutritional supplementation.
Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
Hassanein, Tarek , Keaveny, Andrew P. , Mantry, Parvez , Kittelson, John, Helmke, Steve M. , Everson, Gregory T. , Investigators, for the SHUNT‐V, McRae, Michael P , Everson, Gregory T , Keaveny, Andrew P , Smith, Alastair D. , McRae, Michael P. , Investigators, for the SHUNT‐V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 25, 2024 | Volume: 60 | Issue: 3 | Pages: 405-406

10.1111/apt.18128 | PMID 38924551 Get It

LINKED CONTENTThis article is linked to Hassanein et al papers. To view these articles, visit https://doi.org/10.1111/apt.18054 and https://doi.org/10.1111/apt.18113
Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation
Lorenz, Elizabeth C. , Liang, Yun , Dhala, Atiya , Kennedy, Cassie C. , Kennedy, Cassie C , Smith, Byron H. , Park, Walter D. , Bentall, Andrew , Waterman, Amy D , Hickson, LaTonya J. , Rule, Andrew D. , Cheville, Andrea , LeBrasseur, Nathan K. , Stegall, Mark D.

Mayo Clinic

Transplantation | June 24, 2024 | Volume: 108 | Issue: 12 | Pages: 2434-2445

10.1097/tp.0000000000005103 | PMID 38913783 Get It

Background. Chronic systemic inflammation is associated with mortality in patients with chronic kidney disease, cardiovascular disease, and diabetes. The goal of this study was to examine the relationship between pretransplant inflammatory biomarkers (growth differentiation factor-15 [GDF-15], interleukin-6 [IL-6], soluble tumor necrosis factor receptor-1, monokine induced by gamma interferon/chemokine [C-X-C motif] ligand 9 [MIG/CXCL9], monocyte chemoattractant protein-1, soluble FAS, tumor necrosis factor-α, interleukin-15, and interleukin-1β) and death with function (DWF) after kidney transplantation (KT). Methods. We retrospectively measured inflammatory biomarker levels in serum collected up to 1 y before KT (time from blood draw to KT was 130 ± 110 d) in recipients transplanted between January 2006 and December 2018. Kaplan-Meier estimation, Cox regression, and Gradient Boosting Machine modeling were used to examine the relationship between inflammatory biomarkers and DWF. Results. Our cohort consisted of 1595 KT recipients, of whom 62.9% were male and 83.2% were non-Hispanic White. Over a mean follow-up of 7.4 ± 3.9 y, 21.2% of patients (n = 338) experienced DWF. Patients with the highest quartile levels of GDF-15 (>4766 pg/mL), IL-6 (>6.11 pg/mL), and MIG/CXCL9 (> 5835 pg/mL) had increased rates of DWF, and each predicted mortality independently of the others. When adjusted for clinical factors (age, diabetes, etc), the highest quartile levels of GDF-15 and IL-6 remained independently associated with DWF. Adding inflammatory markers to a clinical Cox model improved the C-statistic for DWF from 0.727 to 0.762 using a Gradient Boosting Machine modeling approach. Conclusions. These findings suggest that pre-KT serum concentrations of GDF-15, IL-6, and MIG/CXCL9 may help to risk stratify and manage patients undergoing KT and suggests that chronic inflammation may play a role in mortality in KT recipients.
The impact of donating milk on the health of milk donors and their infants: A systematic review and meta‐analysis protocol
Berg, Alaina , Rani, Uzma , Smith, Abigail , Imdad, Aamer , Murad, Mohammad H, Imdad, Aamer , Berg, Alaina C , Colaizy, Tarah T. , Evans, James A. , Murad, M. Hassan , Bhutta, Zulfiqar A

Mayo Clinic

JPGN Reports | June 24, 2024 | Volume: 5 | Issue: 3 | Pages: 347-352

10.1002/jpr3.12101 | PMID 39149172 Get It

Abstract Objectives Breast milk is the recommended nutritional source for newborns and has been associated with decreased morbidity in low‐birth‐weight and preterm infants. In situations where breast milk is not available, donor breast milk is an alternative. Milk banking is becoming increasingly common worldwide to meet this need. Although the benefits of donor breast milk for the recipient infant are well established, the health impact on the breast milk donor and the infant of the breast milk donor is an area of current research. We aim to synthesize and evaluate the available evidence regarding the impact of donating breast milk on the health, lactation, and well‐being of the breast milk donor, and the health and growth of the infant of the breast milk donor. Methods We will search electronic databases, grey literature, and the websites of relevant international organizations. We will include studies that involve lactating women and their infants, healthy or with health conditions, who donate breast milk, without restrictions on study date, language, or study design. If sufficient homogeneity exists between studies, we will complete meta‐analyses. We will evaluate the risk of bias using the Risk of Bias tool or the Cochrane Risk of Bias in Non‐Randomized Studies tool. We will evaluate the overall certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Conclusion In this systematic review and meta‐analysis, we will summarize the current literature regarding the effects of human milk donation on human milk donors and their infants.
The impact of storage, handling, and treatment on nutritional quality and safety of animal milk: A protocol for the systematic review and meta‐analysis
Alwasila, Roba , Berg, Alaina , Smith, Abigail , Imdad, Aamer , Murad, Mohammad Hassan, Imdad, Aamer , Berg, Alaina C , Colaizy, Tarah T. , Evans, James A. , Murad, M. Hassan , Bhutta, Zulfiqar A

Mayo Clinic

JPGN Reports | June 24, 2024 | Volume: 5 | Issue: 3 | Pages: 342-346

10.1002/jpr3.12102 | PMID 39149198 Get It

Abstract Objectives Human milk has been shown to reduce severe morbidity in preterm/low‐birth‐weight infants and is therefore the recommended nutritional source. When infants cannot receive maternal milk, donor human milk (DHM) is recommended. The use of human milk banking facilities is increasing to meet the need for DHM. DHM is unique compared to maternal milk as it must be processed and stored. The processing and storage of animal milk has been more rigorously studied than human milk and can serve as proxy to create DHM banking guidelines. Methods and Analysis We will search electronic databases, grey literature, and the websites of relevant international organizations. We will include studies that evaluated the impact of storage, handling, and treatment on the nutritional quality and safety of animal milk. We will not restrict study date, language, or design. If sufficient homogeneity exists between studies, we will conduct a meta‐analysis. We will evaluate the methodological quality of each study using the SYRCLE's (Systematic Review Centre for Laboratory Animal Experimentation) risk of bias tool. (1) We will evaluate the overall certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Conclusion In this systematic review and meta‐analysis, commissioned by the World Health Organization, we will synthesize the available literature regarding the impact of various storage, handling, and treatment practices on the nutritional quality and safety of animal milk.
Advanced Heart Failure Characteristics and Outcomes in Women and Men
Farooqui, Naba , Killian, Jill M. , Smith, Jamie, Redfield, Margaret M. , Dunlay, Shannon M. , Dunlay, Shannon , Smith, Jamie L

Mayo Clinic

Journal of the American Heart Association | June 21, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.123.033374 | PMID 38904243 Get It

Background The epidemiology and pathophysiology of heart failure (HF) differ in women and men. Whether these differences extend to the subgroup of patients with advanced HF is not well defined. Methods and Results This is a retrospective cohort study of all adult Olmsted County, Minnesota residents with advanced HF (European Society of Cardiology criteria) from 2007 to 2017. Differences in survival and hospitalization risks in women and men following advanced HF development were examined using Cox proportional hazard regression and Andersen‐Gill models, respectively. Of 936 individuals with advanced HF, 417 (44.6%) were women and 519 (55.4%) were men (self‐reported sex). Time from development of HF to advanced HF was similar in women and men (median 3.2 versus 3.6 years). Women were older at diagnosis (mean age 79 versus 75 years), less often had coronary disease and hyperlipidemia, but more often had hypertension and depression ( P <0.05 for each). Advanced HF with preserved ejection fraction was more prevalent in women than men (60% versus 30%, p<0.001). There were no differences in adjusted risks of all‐cause mortality (hazard ratio [HR], 0.89 [95% CI, 0.77–1.03]), cardiovascular mortality (HR, 0.85 [95% CI, 0.70–1.02]), all‐cause hospitalizations (HR, 1.04 [95% CI, 0.90–1.20]), or HF hospitalizations (HR, 0.91 [95% CI, 0.75–1.11]) between women and men. However, adjusted cardiovascular mortality was lower in women versus men with advanced HF with reduced ejection fraction (HR, 0.72 [95% CI, 0.56–0.93]). Conclusions Women more often present with advanced HF with preserved ejection fraction and men with atherosclerotic disease and advanced HF with reduced ejection fraction. Despite these differences, survival and hospitalization risks are largely comparable in women and men with advanced HF.
MDB-10. DIVERGENT MEDULLOBLASTOMA CHROMATIN STATES DISCLOSE KDM2B AS A NOVEL ONCOGENIC DEPENDENCY
Tao, Ran , Smith, Kyle , Djekidel, Nadhir, Darrow, Emily, Lin, Hong , Hadley, Jennifer , Batts, Melissa , Bhanu, Natarajan V. , García, Benjamin A. , Tao, Ran, Erkek, Serap , Matsui, Yurika , Xu, Beisi , Gao, Qingsong , Li, Yiran, Kumar, Rahul , Paul, Leena , Kutscher, Lena M. , Zhou, Xin , Orr, Brent A. , Robinson, Giles , Wu, Gang , Korbel, Jan O. , Peng, Jamy C. , Pfister, Stefan M. , Northcott, Paul A

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.459 Get It

Abstract BACKGROUND Medulloblastoma (MB) is a highly malignant childhood cerebellar tumor comprising a collection of molecularly and clinically distinct entities. Group 3 and Group 4-MB subgroups originate from overlapping progenitor pools of the developing rhombic lip when neuronal differentiation hierarchies are subverted through somatic alterations. Mutations suspected to deregulate the activity of chromatin-modifying genes are pervasive in Group 3 and Group 4-MB. However, the molecular consequences of these alterations remain largely undefined. METHODS We characterized the chromatin landscape of fifty-two primary MBs using chromatin immunoprecipitation followed by sequencing (ChIP-seq) for six histone modifications and performed multi-modal integration with sample-matched somatic lesions, genome-wide DNA methylation, and transcriptomic profiles. RESULTS Analysis of differential chromatin states across MB subgroups using a Hidden Markov Model revealed a significant enrichment of the bivalent enhancer state (EnhBiv; marked by coincident H3K4me1 and H3K27me3) in Group 4-MB which localized to promoters of neurodevelopmental genes and transcription factors. To functionally dissect the pathogenetic significance of the enriched EnhBiv state in Group 4-MB, we sought to identify key regulators that confer this state. Integrative bioinformatics coupled with CUT&RUN analysis revealed significant enrichment of KDM2B, a histone lysine demethylase overexpressed in Group 4-MB, in gene promoters marked by the EnhBiv state. CRISPR gene targeting or targeted protein degradation of KDM2B selectively suppressed growth of Group 3 and Group 4-MB models in vitro and in vivo. Mechanistically, inhibition of KDM2B disrupted chromatin bivalency by blocking PRC2 complex recruitment and reducing H3K27me3 deposition, profoundly derepressing PRC2 targets involved in neuronal differentiation. CONCLUSIONS Our comprehensive characterization of the MB chromatin landscape in a large cohort of primary tumors provides unprecedented insights into the epigenetic basis of MB subgroups, implicating novel mechanisms of tumorigenesis, and nominating KDM2B as a selective dependency in Group 3/4-MB that should be prioritized as an attractive therapeutic target.
Mesangial Expansion by Morphometry at 5 y After Kidney Transplantation: Incidence, Risk Factors, and Association With Graft Loss
Đenić, Aleksandar , Buglioni, Alessia , Túrkevi-Nagy, Sándor , Mejia, Mateo Velasquez , Subramani, Rashmi , Kukla, Aleksandra , Diwan, Tayyab S. , Grande, Joseph P. , Denic, Aleksandar , Smith, Byron H. , Park, Walter D. , Stegall, Mark D.

Mayo Clinic

Transplantation Direct | June 17, 2024 | Volume: 10 | Issue: 7 | Pages: e1652

10.1097/txd.0000000000001652 | PMID 38881746 Get It

Background. Mesangial expansion (ME) is an understudied histologic lesion in renal allografts. The current Banff mm score is not reproducible and may miss important ME features. The study aimed to improve the quantification of ME using morphometry, assess changes over time, and determine its association with allograft loss. Methods. We studied ME in 1-y and 5-y surveillance biopsies in 835 kidney transplants performed between January 2000 and December 2013. ME was assessed using the Banff mm score by a central pathologist and by morphometry. We derived 3 different morphometric measures: (1) %ME mm (%glomeruli with ME in ≥2 lobules, like Banff mm); (2) %MEany (%glomeruli with any ME lesion); and (3) %ME area (sum of all ME areas/all glomerular tuft areas). Unadjusted and adjusted Cox models assessed the risk of death-censored allograft loss. Results. From 1- to 5-y biopsies, the mean Banff mm score increased from 0.18 to 0.34, whereas %ME mm increased from 2.5% to 13.3%. Banff mm score had modest correlations with morphometric ME measures. Moderate-severe %ME mm was present in 20.1% of 5-y biopsies, whereas only 6.6% of Banff mm scores were. In general, higher ME on both 1- and 5-y biopsies was associated with a deceased donor, older recipient age, recipient diabetes/obesity (present in >50% of severely affected biopsies), higher hemoglobin A1c at 5 y posttransplant, and recurrent kidney disease. Higher ME on 5-y biopsies was associated with delayed graft function. A higher Banff mm score at 1-y biopsy and morphometry ME measures at 5-y biopsy were associated with rejection during the first year posttransplant. Morphometric ME measures were associated with allograft loss independent of Banff scores and all clinical characteristics, including kidney function and recurrent disease. The model with %MEany had the highest c-statistic (0.872). Conclusions. Banff mm score underestimates the pervasiveness of ME in 5-y biopsies. ME is common and associated with alloimmune and nonalloimmune causes of graft loss.
Mohs Micrographic Surgery With Immunohistochemistry for the Treatment of Periocular Melanoma In Situ
McInnis‐Smith, Kerri , Asamoah, Eucabeth, Demer, Addison M. , Sharma, Kannan , Yu, Caroline , Tooley, Andrea A. , McInnis-Smith, Kerri M , Bradley, Elizabeth A. , Wagner, Lilly H.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | June 17, 2024 | Volume: 41 | Issue: 1 | Pages: 78-83

10.1097/iop.0000000000002729 | PMID 38884530 Get It

Purpose: Mohs micrographic surgery with immunohistochemistry allows for same-day comprehensive margin assessment of melanoma in situ prior to subspecialty reconstruction. This study describes the oncologic and reconstructive outcomes of eyelid and periorbital melanoma in situ and identifies risk factors for complex reconstructive demands. Methods: Retrospective case series of all patients treated with Mohs micrographic surgery with immunohistochemistry for melanoma in situ affecting the eyelids or periorbital region from 2008 to 2018 at a single institution. Tumors were assigned to the eyelid group if the clinically visible tumor involved the skin inside the orbital rim. Reconstructive variables were compared between the eyelid and periorbital cohorts. Results: There were 24 eyelid and 141 periorbital tumors included. The initial surgical margin for all tumors was 5.34 ± 1.54 mm and multiple Mohs stages were required in 24.2% of cases. Eyelid tumors included more recurrences (p = 0.003), and the average defect size was larger (14.0 ± 13.3 cm2 vs. 7.7 ± 5.4 cm2, p = 0.03). Risk factors for complex reconstruction included: initial tumor diameter >2 cm (odds ratio [OR]: 3.84, 95% confidence interval [CI]: 1.95–7.57) and eyelid involved by initial tumor (OR: 4.88, 95% CI: 1.94–12.28). At an average follow-up of 4.8 years, there were no melanoma-related deaths and 1 local recurrence (0.6% recurrence rate). Conclusions: Mohs micrographic surgery with immunohistochemistry achieves excellent local control rates for periocular melanoma in situ. An initial surgical margin of 5 mm is frequently insufficient to achieve clear margins. The resulting defects are large, and the complexity of reconstruction can be predicted by tumor size and clinical involvement of eyelid skin.